Skip to main content
UniHealth

Doctor search

Elwyn C Cabebe, MD

Medical Oncology · Stanford

NPI 1821067281

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
21
5 carriers
Office
1
Since medical school
24 years
University of Vermont College of Medicine, 2002

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

21 plans · 5 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cabebe’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

21 of 21 plans

Plans whose provider directory lists this clinician
Alignment Health Advantage PPO (PPO)Alignment Health PlanListedOct 3, 2026
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Astiva Health C-SNP WOW - NorCal (HMO C-SNP)Astiva HealthListedSep 27, 2026
Astiva Health Premier Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Astiva Health Savings Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Blue Shield Inspire (HMO)Blue Shield of CaliforniaListedAug 26, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A84778 · Current

Licensed to practise in California · since 2003 · expires 2027-10-31 · University of Vermont College of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Hospice and Palliative Medicine
  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
  • Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend it
    Overall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health

Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at El Camino Health
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.291BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.393BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.96 (0.12 to 1.79) · 2,340 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.02 (0.76 to 1.28)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths167.38 (125.03 to 209.73) · 96 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.6 · 68 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 185 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.8 · 200 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8.9 · 814 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13 · 842 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 361 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.6 · 4,633 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.34) · 11,474 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.1 to 0.45) · 11,626 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.14 (1.39 to 4.9) · 2,814 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths2 (0.61 to 3.39) · 1,327 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.8 to 3.43) · 2,641 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths9.39 (4.18 to 14.6) · 1,287 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths6.57 (3.47 to 9.68) · 1,308 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.14 (0.71 to 3.57) · 827 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.6 (0.05 to 1.15) · 9,460 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.5 · 122 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.993No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.706No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.376No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.5 · 218 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.5 · 962 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits3.8 · 200 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-17 · 922 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits18.6 · 860 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.7 · 827 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.1 (4.5 to 8.2) · 313 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13.4 (10.6 to 16.5) · 313 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6.1 · 144 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.7 · 237 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.8 (10 to 16.1) · 1,639 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.8 to 1.1) · 1,619 casesNo differentJan 2024 – Dec 2024

What patients said (1,535 patients answered, 22% of those asked)

Patient survey stars by topic at El Camino Health
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at El Camino Health
Room was "always" clean75%
Nurses "always" communicated well79%
Doctors "always" communicated well81%
Staff "always" explained61%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand75%
Nurses "always" listened carefully76%
Nurses "always" treated them with courtesy and respect87%
"Always" quiet at night47%
"YES", patients would definitely recommend the hospital80%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Good Samaritan Hospital

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Good Samaritan Hospital
Clostridium Difficile (C.Diff)Infections0.337BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.75 (0 to 1.67) · 1,340 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.84 (0.54 to 1.14)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths143.59 (98.7 to 188.49) · 98 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 45 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 100 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.7 · 270 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11.3 · 573 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.6 · 820 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.5 · 482 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.3 · 3,711 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.12 (0 to 0.3) · 8,866 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.01 to 0.38) · 9,051 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.65 (0.74 to 4.56) · 1,929 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.8 (0.21 to 3.39) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.33 (0.88 to 3.78) · 1,836 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.73 (0 to 13.46) · 669 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.58 (3.96 to 11.19) · 654 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.59 (0.13 to 3.04) · 496 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.27 (0 to 0.87) · 7,373 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.1 · 152 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections1.08No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.542No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.484No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.565No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.8 · 327 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits24.2 · 703 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits61.1 · 289 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits36.3 · 665 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits25.4 · 856 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits19 · 978 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits6.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits12.3 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits21.2 · 135 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.8 (10.1 to 18.6) · 129 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (0.9 to 1.5) · 531 casesNo differentJan 2024 – Dec 2024

What patients said (704 patients answered, 24% of those asked)

Patient survey stars by topic at Good Samaritan Hospital
Cleanliness3
Nurse communication3
Doctor communication2
Communication about medicines2
Discharge information3
Overall hospital rating2
Quietness1
Recommend hospital3
Share of patients giving the best answer at Good Samaritan Hospital
Room was "always" clean66%
Nurses "always" communicated well75%
Doctors "always" communicated well71%
Staff "always" explained54%
Yes, staff "did" give patients this information83%
Yes, staff "did" give patients information about help after discharge81%
Doctors "always" explained things so they could understand66%
Doctors "always" listened carefully69%
Doctors "always" treated them with courtesy and respect78%
Patients who gave a rating of "9" or "10" (high)63%
Staff "always" explained new medications68%
Nurses "always" explained things so they could understand69%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night38%
"YES", patients would definitely recommend the hospital67%
Staff "always" explained possible side effects40%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$279,923

Medicare paid this office $279,923 for 843 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)403$150,084$147
Return visit (30+ min)425$51,693$92
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes69$26,471$106
New patient visit (60+ min)113$19,801$175
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's589$15,690$15
See all 6 services
Every Original Medicare service billed
Long return visit (40+ min)403$150,084$147
Return visit (30+ min)425$51,693$92
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes69$26,471$106
New patient visit (60+ min)113$19,801$175
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's589$15,690$15
Initial hospital care with moderate level of medical decision making at least 75 minutes88$15,282$154

Who their Medicare patients are

843 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 18% · Women 65% · Also on Medicaid 9% · Health risk score 1.65. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 75% · Cancer 59% · Diabetes 29% · Coronary heart disease 27% · Chronic kidney disease 25% · Atrial fibrillation 23% · Heart failure 16% · Depression 16% · COPD 14% · Stroke 11% · Dementia 8%.

The office billed $1,272,108, Medicare allowed $373,235 and paid $279,923; for 3,114 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20248433,114771.65$1,272,108$279,923
20238662,055771.58$961,612$227,255
20229132,187761.59$1,196,228$231,328
20219072,187761.66$1,343,598$241,776
20208182,006761.84$649,643$160,722
20199863,252771.77$617,287$264,536
201898593,407761.85$7,768,547$1,942,793
2017969197,255761.78$14,544,346$3,306,390
2016856186,970761.72$10,328,274$3,226,101
2015853209,693761.63$9,852,540$3,241,497
2014907178,255761.53$10,033,025$3,192,881
2013755156,960751.47$9,379,166$3,139,924

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Long return visit (40+ min)411$120,152$120
Return visit (30+ min)415$44,268$79
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes81$29,048$107
New patient visit (60+ min)111$17,233$155
Initial hospital care with moderate level of medical decision making at least 75 minutes90$16,096$156

2022: 5 services

Original Medicare services billed in 2022
Long return visit (40+ min)427$129,726$121
Return visit (30+ min)455$46,323$74
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes90$31,473$92
New patient visit (60+ min)110$17,368$158
Initial hospital care with moderate level of medical decision making at least 75 minutes34$6,085$179

2021: 5 services

Original Medicare services billed in 2021
Long return visit (40+ min)449$140,215$126
Return visit (30+ min)477$44,233$75
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes100$32,361$95
New patient visit (60+ min)115$19,520$170
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,181$185

2020: 5 services

Original Medicare services billed in 2020
Return visit (30+ min)681$86,002$66
Long return visit (40+ min)161$28,220$98
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes88$27,435$97
New patient visit (60+ min)88$13,343$152
Initial hospital care with moderate level of medical decision making at least 75 minutes26$5,454$188

2019: 5 services

Original Medicare services billed in 2019
Return visit (30+ min)832$121,212$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes173$86,186$95
Long return visit (40+ min)190$33,998$94
Initial hospital care with moderate level of medical decision making at least 75 minutes76$14,002$184
New patient visit (60+ min)67$9,091$136

2018: 29 services

Original Medicare services billed in 2018
Injection, pembrolizumab, 1 mg11$249,125None
Injection, pegfilgrastim, 6 mg21$234,669None
Return visit (30+ min)827$148,980$77
Injection, denosumab, 1 mg25$118,902None
Injection, epoetin alfa, (for non-esrd use), 1000 units28$63,348None
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes145$53,550$91
Administration of chemotherapy into vein, 1 hour or less71$41,741$144
Long return visit (40+ min)177$36,896$110
Not otherwise classified, antineoplastic drugs20$22,392None
Injection, palonosetron hcl, 25 mcg38$19,144None
New patient visit (60+ min)118$18,143$154
Initial hospital care with moderate level of medical decision making at least 75 minutes70$13,587$176
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count398$9,335$9
Injection of additional new drug or substance into vein59$8,171$17
Injection of drug or substance under skin or into muscle77$6,035$18
Administration of additional new drug or substance into vein, 1 hour or less26$5,652$69
Administration of chemotherapy into vein, each additional hour29$4,449$31
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less41$4,379$31
Drawing of blood for a medical problem13$2,735$94
Administration of additional new drug or substance into vein using push technique11$2,550$59
Irrigation of implanted venous access drug delivery device21$1,492$24
Injection of drug or substance into vein13$1,356$45
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less11$1,313$69
Injection, carboplatin, 50 mg17$894None
Application of on-body injector for under skin injection17$859$20
Injection, dexamethasone sodium phosphate, 1 mg52$213None
Injection, ranitidine hydrochloride, 25 mg15$180None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg15$84None
Injection, diphenhydramine hcl, up to 50 mg40$70None

2017: 39 services

Original Medicare services billed in 2017
Injection, pegfilgrastim, 6 mg35$399,776None
Injection, bevacizumab, 10 mg11$325,844None
Injection, rituximab, 100 mg17$263,028None
Injection, denosumab, 1 mg31$205,922None
Return visit (30+ min)817$204,018$97
Injection, epoetin alfa, (for non-esrd use), 1000 units35$132,081None
Administration of chemotherapy into vein, 1 hour or less96$84,860$143
Long return visit (40+ min)224$53,768$131
Injection, palonosetron hcl, 25 mcg56$40,703None
New patient visit (60+ min)188$34,999$186
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes85$29,463$93
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less86$23,741$31
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count504$20,351$10
Injection of drug or substance under skin or into muscle113$18,426$26
Injection, ferric carboxymaltose, 1 mg13$16,846None
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle16$12,177$76
Injection, fosaprepitant, 1 mg15$10,203None
Administration of additional new drug or substance into vein, 1 hour or less41$9,615$67
Injection of additional new drug or substance into vein87$8,917$23
Administration of chemotherapy into vein, each additional hour52$8,649$28
Administration of additional new drug or substance into vein using push technique21$6,175$64
Initial hospital care with moderate level of medical decision making at least 75 minutes29$5,253$181
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less30$5,219$70
Drawing of blood for a medical problem15$4,144$101
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg11$3,443None
Irrigation of implanted venous access drug delivery device32$2,476$23
Not otherwise classified, antineoplastic drugs50$2,072None
Injection, zoledronic acid, 1 mg15$1,899None
Injection, carboplatin, 50 mg25$1,768None
Injection, paclitaxel, 1 mg18$1,536None
Injection of drug or substance into vein14$1,319$57
Short return visit (20+ min)14$1,107$62
Infusion into a vein for hydration, each additional hour11$632$15
Insertion of needle into vein for collection of blood sample123$429$3
Injection, dexamethasone sodium phosphate, 1 mg92$396None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg22$253None
Injection, diphenhydramine hcl, up to 50 mg72$185None
Infusion, normal saline solution , 1000 cc12$65None
Injection, ondansetron hydrochloride, per 1 mg13$35None

2016: 46 services

Original Medicare services billed in 2016
Injection, pegfilgrastim, 6 mg27$398,009None
Injection, bevacizumab, 10 mg15$370,774None
Injection, rituximab, 100 mg11$227,453None
Injection, bortezomib, 0.1 mg12$201,697None
Return visit (30+ min)749$187,412$94
Injection, denosumab, 1 mg23$147,199None
Injection, epoetin alfa, (for non-esrd use), 1000 units27$134,881None
Administration of chemotherapy into vein, 1 hour or less77$75,661$140
Injection, palonosetron hcl, 25 mcg48$37,460None
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes107$36,609$91
Short return visit (20+ min)214$36,232$65
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less76$25,616$30
New patient visit (60+ min)129$23,774$184
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count441$20,165$10
Injection of drug or substance under skin or into muscle91$18,192$25
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle34$15,532$75
Administration of additional new drug or substance into vein, 1 hour or less37$13,361$64
Long return visit (40+ min)78$12,121$133
Administration of chemotherapy into vein using push technique11$10,603$114
Administration of chemotherapy into vein, each additional hour46$8,866$28
Injection of additional new drug or substance into vein61$6,001$23
Initial hospital care with moderate level of medical decision making at least 75 minutes33$5,949$180
Administration of additional new drug or substance into vein using push technique14$5,412$64
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less27$4,521$67
Drawing of blood for a medical problem11$3,851$96
Injection, zoledronic acid, 1 mg20$3,176None
Injection, paclitaxel, 1 mg19$2,963None
Biopsy of bone marrow12$2,012$168
Injection, carboplatin, 50 mg21$2,008None
Infusion into a vein for hydration, 31-60 minutes18$2,001$57
Irrigation of implanted venous access drug delivery device19$1,628$24
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle11$1,560$33
Injection of drug or substance into vein12$988$58
Aspiration of bone marrow sample for diagnosis11$910$83
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion12$865$20
Infusion into a vein for hydration, each additional hour11$644$15
Injection, heparin sodium, (heparin lock flush), per 10 units14$499None
Injection, dexamethasone sodium phosphate, 1 mg65$457None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg19$404None
Insertion of needle into vein for collection of blood sample104$380$3
Injection, ranitidine hydrochloride, 25 mg38$298None
Injection, diphenhydramine hcl, up to 50 mg61$145None
Infusion, normal saline solution , 1000 cc18$95None
Injection, ondansetron hydrochloride, per 1 mg13$56None
Unclassified drugs11$9None
Infusion, normal saline solution, 250 cc12$8None

2015: 38 services

Original Medicare services billed in 2015
Injection, bevacizumab, 10 mg11$504,740None
Injection, pegfilgrastim, 6 mg37$473,194None
Injection, pemetrexed, not otherwise specified, 10 mg11$323,736None
Injection, denosumab, 1 mg22$151,425None
Return visit (30+ min)632$119,991$95
Administration of chemotherapy into vein, 1 hour or less75$88,045$140
Short return visit (20+ min)417$86,468$65
Injection, epoetin alfa, (for non-esrd use), 1000 units25$83,943None
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes106$44,458$93
Injection, palonosetron hcl, 25 mcg47$34,854None
New patient visit (60+ min)175$32,211$184
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less74$26,427$30
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle37$22,222$77
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count412$17,546$10
Injection of drug or substance under skin or into muscle80$16,118$25
Administration of additional new drug or substance into vein, 1 hour or less38$12,026$64
Administration of chemotherapy into vein, each additional hour45$8,756$28
Long return visit (40+ min)59$8,584$130
Injection, zoledronic acid, 1 mg17$8,298None
Initial hospital care with moderate level of medical decision making at least 75 minutes31$6,152$181
Administration of additional new drug or substance into vein using push technique15$5,851$63
Injection of additional new drug or substance into vein56$5,722$23
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg11$4,616None
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less25$4,010$70
Injection, paclitaxel, 1 mg21$3,488None
Injection, carboplatin, 50 mg27$2,805None
Infusion into a vein for hydration, 31-60 minutes17$1,838$59
Irrigation of implanted venous access drug delivery device28$1,570$24
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$1,293$65
Injection, heparin sodium, (heparin lock flush), per 10 units22$885None
Infusion into a vein for hydration, each additional hour14$538$15
Injection, dexamethasone sodium phosphate, 1 mg69$470None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg20$360None
Injection, ranitidine hydrochloride, 25 mg48$294None
Injection, diphenhydramine hcl, up to 50 mg61$152None
Insertion of needle into vein for collection of blood sample25$79$3
Injection, ondansetron hydrochloride, per 1 mg21$65None
Infusion, normal saline solution , 1000 cc20$63None

2014: 47 services

Original Medicare services billed in 2014
Injection, pegfilgrastim, 6 mg42$503,587None
Injection, bortezomib, 0.1 mg11$312,340None
Injection, pemetrexed, not otherwise specified, 10 mg12$300,875None
Injection, denosumab, 1 mg24$128,766None
Short return visit (20+ min)635$119,836$64
Administration of chemotherapy into vein, 1 hour or less75$84,515$136
Injection, darbepoetin alfa, 1 microgram (non-esrd use)11$72,886None
Injection, epoetin alfa, (for non-esrd use), 1000 units29$56,037None
Return visit (30+ min)331$55,019$97
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes150$50,981$92
Injection, palonosetron hcl, 25 mcg54$38,578None
New patient visit (60+ min)179$32,895$184
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less77$27,591$30
Injection, zoledronic acid, 1 mg24$24,304None
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle26$19,233$75
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram13$19,153None
Initial hospital care with moderate level of medical decision making at least 75 minutes88$16,148$179
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count384$15,475$10
Injection of drug or substance under skin or into muscle95$15,210$24
Administration of additional new drug or substance into vein, 1 hour or less48$14,791$63
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less46$9,393$70
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes70$8,901$64
Long return visit (40+ min)64$8,501$131
Administration of chemotherapy into vein, each additional hour51$7,859$28
Injection of additional new drug or substance into vein62$7,210$22
Administration of additional new drug or substance into vein using push technique18$5,728$62
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg11$4,954None
Injection, carboplatin, 50 mg35$3,240None
Injection, paclitaxel, 30 mg25$2,962None
Biopsy of bone marrow15$2,312$144
Infusion into a vein for hydration, 31-60 minutes14$2,202$58
Aspiration of bone marrow sample for diagnosis17$2,157$114
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle13$1,628$31
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour20$1,137$18
Infusion into a vein for hydration, each additional hour13$791$15
Irrigation of implanted venous access drug delivery device14$637$24
Injection, dexamethasone sodium phosphate, 1 mg64$509None
Injection, ranitidine hydrochloride, 25 mg49$407None
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion13$400$20
Insertion of needle into vein for collection of blood sample88$315$3
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg25$255None
Blood test, comprehensive group of blood chemicals16$240$14
Injection, heparin sodium, (heparin lock flush), per 10 units11$226None
Injection, diphenhydramine hcl, up to 50 mg60$178None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service14$177$12
Injection, ondansetron hydrochloride, per 1 mg21$136None
Infusion, normal saline solution , 1000 cc27$87None

2013: 50 services

Original Medicare services billed in 2013
Injection, rituximab, 100 mg14$290,236None
Injection, pegfilgrastim, 6 mg32$286,964None
Administration of chemotherapy into vein, 1 hour or less88$108,407$147
Return visit (30+ min)536$108,039$93
Injection, epoetin alfa, (for non-esrd use), 1000 units34$107,678None
Injection, darbepoetin alfa, 1 microgram (non-esrd use)21$107,305None
Injection, denosumab, 1 mg12$102,980None
Short return visit (20+ min)360$86,803$67
Injection, zoledronic acid (zometa), 1 mg16$43,581None
Injection, filgrastim (g-csf), 480 mcg17$43,001None
Zoldedronic acid 1mg20$37,361$136
Injection, palonosetron hcl, 25 mcg50$33,594None
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes96$31,331$89
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less86$26,552$32
Injection of drug or substance under skin or into muscle102$20,464$25
New patient visit (60+ min)113$20,433$181
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle33$17,738$77
Injection, triptorelin pamoate, 3.75 mg12$14,318None
Administration of additional new drug or substance into vein, 1 hour or less45$13,186$72
Administration of chemotherapy into vein, each additional hour61$12,493$30
Injection, fosaprepitant, 1 mg16$11,407None
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less38$9,791$77
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes60$9,427$62
Administration of chemotherapy into vein using push technique16$9,425$115
Initial hospital care with moderate level of medical decision making at least 75 minutes48$8,538$171
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg12$7,646None
Administration of additional new drug or substance into vein using push technique24$5,693$64
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion55$5,656$18
Long return visit (40+ min)44$5,598$127
Injection of additional new drug or substance into vein60$3,820$22
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count132$3,217$10
Drawing of blood for a medical problem11$2,817$97
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour42$2,449$21
Injection, paclitaxel, 30 mg18$2,373None
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle20$2,333$32
Injection, carboplatin, 50 mg23$1,660None
Infusion into a vein for hydration, 31-60 minutes12$1,375$60
Hospital discharge day management, more than 30 minutes11$1,043$95
Infusion, normal saline solution , 1000 cc93$898None
Injection, dexamethasone sodium phosphate, 1 mg70$642None
Blood test, comprehensive group of blood chemicals37$555$14
Irrigation of implanted venous access drug delivery device11$547$26
Injection, ranitidine hydrochloride, 25 mg41$366None
Injection, ondansetron hydrochloride, per 1 mg25$366None
Injection, diphenhydramine hcl, up to 50 mg58$204None
Insertion of needle into vein for collection of blood sample23$71$3
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg13$47None
Infusion, normal saline solution, 250 cc52$35None
Infusion, normal saline solution, sterile (500 ml = 1 unit)41$25None
Injection, magnesium sulfate, per 500 mg11$13None

Medicaid work

$2,733 in 2023

Medicaid paid $2,733 for 67 billed services this clinician did in 2023, up to 18 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
Long return visit (40+ min)55$2,342
Return visit (30+ min)12$390
Medicaid work by year
202367218$2,733
202262117$2,194
202113112$359
202042113$921
201929114$397
201812112$0
See the largest Medicaid services in earlier years

2022

Largest Medicaid services in 2022
Long return visit (40+ min)62$2,194

2021

Largest Medicaid services in 2021
Long return visit (40+ min)13$359

2020

Largest Medicaid services in 2020
Return visit (30+ min)42$921

2019

Largest Medicaid services in 2019
Return visit (30+ min)29$397

2018

Largest Medicaid services in 2018
URINE PREGNANCY TEST12$0

Drugs they prescribed that Part D paid

$1,283,772

Pharmacies billed $1,283,772 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

209 generic and 102 brand-name prescriptions · $1,283,772 in drug cost · 11 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Kisqali13$195,079$15,006
Xarelto13$21,470$1,652
Eliquis12$8,771$731
Anastrozole74$2,023$27
Acyclovir14$323$23
See all 8 drugs
Every Part D drug this clinician prescribed
Kisqali13$195,079$15,006
Xarelto13$21,470$1,652
Eliquis12$8,771$731
Anastrozole74$2,023$27
Acyclovir14$323$23
Letrozole11$235$21
Prochlorperazine Maleate14$161$11
Ondansetron20$135$7

Year by year

Part D prescribing by year
2024311101None33%$1,283,772
202322189None14%$381,781
202222080None22%$929,624
202122184None31%$963,291
20203921336% (24)32%$1,592,339
20194591535% (23)31%$1,626,846
20186361965% (33)None$961,046
20176771844% (29)19%$845,021
20166101685% (31)15%$613,591
20157691835% (36)15%$574,852
20149652117% (66)None$863,058
20131,0772065% (56)None$875,485

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Anastrozole57$2,609$46
Letrozole32$1,386$43
Dexamethasone20$183$9
Ondansetron13$116$9

2022: 3 drugs

Part D drugs prescribed in 2022
Pomalyst20$435,234$21,762
Revlimid22$401,463$18,248
Anastrozole85$2,378$28

2021: 4 drugs

Part D drugs prescribed in 2021
Revlimid28$509,073$18,181
Pomalyst20$410,976$20,549
Anastrozole61$2,511$41
Prednisone13$123$9

2020: 8 drugs

Part D drugs prescribed in 2020
Revlimid64$1,078,923$16,858
Tagrisso13$226,667$17,436
Anastrozole103$3,576$35
Tamoxifen Citrate14$932$67
Metoprolol12$774$65
Hydroxyurea13$707$54
Letrozole13$335$26
Oxycodone11$116$11

2019: 12 drugs

Part D drugs prescribed in 2019
Revlimid49$779,316$15,904
Imbruvica17$223,566$13,151
Xtandi14$161,190$11,514
Eliquis23$21,301$926
Anastrozole88$2,831$32
Tamoxifen Citrate17$1,215$71
Hydroxyurea17$973$57
Letrozole18$417$23
Warfarin16$403$25
Ondansetron27$340$13
Hydrocodone-Acetaminophen15$334$22
Prochlorperazine Maleate18$157$9

2018: 14 drugs

Part D drugs prescribed in 2018
Revlimid22$314,429$14,292
Xtandi18$187,411$10,412
Ibrance12$152,430$12,702
Eliquis28$19,853$709
Exemestane13$9,660$743
Anastrozole179$4,491$25
Hydroxyurea31$2,319$75
Enoxaparin17$2,078$122
Tamoxifen Citrate30$1,694$56
Letrozole35$989$28
Hydrocodone-Acetaminophen19$570$30
Alendronate33$411$12
Dexamethasone13$207$16
Ondansetron12$191$16

2017: 16 drugs

Part D drugs prescribed in 2017
Revlimid23$300,098$13,048
Xtandi12$123,797$10,316
Imbruvica11$121,337$11,031
Zytiga11$87,535$7,958
Eliquis25$15,391$616
Exemestane20$11,003$550
Anastrozole193$4,523$23
Tamoxifen Citrate47$2,271$48
Hydroxyurea41$1,928$47
Letrozole35$850$24
Alendronate38$390$10
Oxycodone-Acetaminophen11$347$32
Hydrocodone-Acetaminophen16$343$21
Gabapentin19$232$12
Lorazepam13$108$8
Dexamethasone12$107$9

2016: 14 drugs

Part D drugs prescribed in 2016
Revlimid11$123,473$11,225
Imbruvica12$121,574$10,131
Anastrozole189$4,762$25
Exemestane12$3,294$274
Tamoxifen Citrate43$2,158$50
Hydrocodone-Acetaminophen16$647$40
Gabapentin32$575$18
Letrozole16$543$34
Hydroxyurea12$502$42
Alendronate37$404$11
Warfarin23$351$15
Dexamethasone12$72$6
Prednisone13$69$5
Acyclovir13$53$4

2015: 17 drugs

Part D drugs prescribed in 2015
Revlimid15$151,802$10,120
Xtandi15$132,355$8,824
Promacta14$82,284$5,877
Exemestane21$6,635$316
Anastrozole251$5,028$20
Tamoxifen Citrate47$2,299$49
Warfarin25$567$23
Letrozole24$521$22
Gabapentin39$504$13
Metoprolol12$497$41
Alendronate34$411$12
Cholestyramine11$388$35
Hydroxyurea13$378$29
Pantoprazole19$323$17
Lorazepam12$286$24
Ondansetron19$227$12
Bupropion12$110$9

2014: 22 drugs

Part D drugs prescribed in 2014
Xtandi24$198,981$8,291
Zytiga18$126,739$7,041
Revlimid13$124,185$9,553
Exemestane48$16,173$337
Anastrozole261$9,641$37
Anagrelide13$3,628$279
Oxycontin11$2,141$195
Tamoxifen Citrate47$1,841$39
Warfarin42$898$21
Alendronate28$543$19
Oxycodone-Acetaminophen20$540$27
Metoprolol11$518$47
Gabapentin31$411$13
Ondansetron32$395$12
Letrozole16$384$24
Pantoprazole24$295$12
Prednisone21$162$8
Prochlorperazine Maleate23$145$6
Dexamethasone11$94$9
Lorazepam13$91$7
Zolpidem12$87$7
Furosemide15$43$3

2013: 26 drugs

Part D drugs prescribed in 2013
Xtandi19$148,535$7,818
Zytiga21$140,390$6,685
Gleevec12$90,510$7,543
Promacta12$61,455$5,121
Nilandron14$22,687$1,620
Exemestane43$17,198$400
Anastrozole285$12,575$44
Letrozole24$4,252$177
Oxycontin11$2,711$246
Tamoxifen Citrate50$1,126$23
Pantoprazole33$853$26
Anagrelide14$792$57
Warfarin34$754$22
Metoprolol15$603$40
Gabapentin45$542$12
Lidocaine-Prilocaine13$475$37
Ondansetron23$408$18
Levetiracetam18$343$19
Citalopram Hbr14$217$15
Prochlorperazine Maleate25$192$8
Zolpidem23$180$8
Dexamethasone11$151$14
Furosemide23$140$6
Prednisone19$129$7
Lorazepam17$113$7
Hydrocodone-Acetaminophen11$89$8

Money from drug and device companies

$543 in 2025

Industry payments by year
202536None$543
202434None$174
202323None$71
202122None$26
202033None$64
20191120None$437

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AstraZeneca Pharmaceuticals LPLynparza$487
4 payments
  • Meals for Lynparza · 2025-12-04 · $121
  • Meals for Lynparza · 2025-07-17 · $125
  • Meals for Lynparza · 2025-06-12 · $106
  • Meals · 2025-05-08 · $135
Caris MPIMi Cancer Seek$31
1 payment
  • Meals for Mi Cancer Seek · 2025-06-05 · $31
Astellas Pharma USVyloy$25
1 payment
  • Meals for Vyloy · 2025-04-14 · $25
See all 6 published payments
Every published payment
AstraZeneca Pharmaceuticals LPMeals · 2025-12-04Lynparza$121
AstraZeneca Pharmaceuticals LPMeals · 2025-07-17Lynparza$125
AstraZeneca Pharmaceuticals LPMeals · 2025-06-12Lynparza$106
Caris MPIMeals · 2025-06-05Mi Cancer Seek$31
AstraZeneca Pharmaceuticals LPMeals · 2025-05-08None$135
Astellas Pharma USMeals · 2025-04-14Vyloy$25
See earlier years (2024, 2023, 2021, 2020, 2019)

2024: $174

Payments by company in 2024
AstraZeneca Pharmaceuticals LPLynparza$137
2 payments
  • Meals for Lynparza · 2024-12-18 · $129
  • Meals for Lynparza · 2024-09-09 · $8
GlaxoSmithKlineOjjaara$19
1 payment
  • Meals for Ojjaara · 2024-12-11 · $19
PfizerInlyta$18
1 payment
  • Education for Inlyta · 2024-09-18 · $18

2023: $71

Payments by company in 2023
ADC Therapeutics AmericaNone$40
2 payments
  • Meals · 2023-05-04 · $13
  • Meals · 2023-04-27 · $28
Foundation MedicineNone$30
1 payment
  • Meals · 2023-11-06 · $30

2021: $26

Payments by company in 2021
Acrotech BiopharmaBeleodaq$14
1 payment
  • Education for Beleodaq · 2021-09-29 · $14
Gilead SciencesNone$12
1 payment
  • Education · 2021-06-01 · $12

2020: $64

Payments by company in 2020
EisaiLenvima$22
1 payment
  • Meals for Lenvima · 2020-02-20 · $22
Karyopharm TherapeuticsXpovio$21
1 payment
  • Meals for Xpovio · 2020-02-17 · $21
EMD SeronoBavencio$21
1 payment
  • Meals for Bavencio · 2020-01-14 · $21

2019: $437

Payments by company in 2019
AmgenNplate$100
4 payments
  • Meals for Nplate · 2019-07-11 · $25
  • Meals for Neulasta · 2019-06-27 · $26
  • Meals for Kyprolis · 2019-05-21 · $21
  • Meals for Nplate · 2019-03-21 · $29
Novartis PharmaceuticalsPromacta$67
3 payments
  • Meals for Promacta · 2019-08-13 · $25
  • Meals for Tasigna · 2019-06-04 · $21
  • Meals for Votrient · 2019-03-26 · $21
AstraZeneca Pharmaceuticals LPTagrisso$66
3 payments
  • Meals for Tagrisso · 2019-07-30 · $24
  • Meals for Tagrisso · 2019-02-06 · $21
  • Meals for Tagrisso · 2019-01-25 · $21
PfizerXalkori$43
2 payments
  • Meals for Xalkori · 2019-08-20 · $22
  • Meals for Ibrance · 2019-01-31 · $21
Foundation MedicineFoundationone$34
1 payment
  • Meals for Foundationone · 2019-06-19 · $34
Gilead SciencesNone$32
2 payments
  • Meals · 2019-05-16 · $16
  • Meals · 2019-04-11 · $16
Bayer HealthCare PharmaceuticalsVitrakvi$24
1 payment
  • Meals for Vitrakvi · 2019-04-03 · $24
Tactile Systems TechnologyFlexitouch$21
1 payment
  • Meals for Flexitouch · 2019-02-20 · $21
EMD SeronoBavencio$19
1 payment
  • Meals for Bavencio · 2019-08-15 · $19
EisaiLenvima$17
1 payment
  • Meals for Lenvima · 2019-03-07 · $17
E.R. Squibb & Sons L.L.C.None$14
1 payment
  • Meals · 2019-10-03 · $14

Professional record

NPI
1821067281
Licence
CA A84778California A84778: Current · expires 2027-10-31
Trained
University of Vermont College of Medicine, 2002 · 24 years ago
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00A847780
Taxonomy
Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0002X (207RH0002X)
Mailing address
2589 Samaritan Dr, San Jose, CA, 95124
NPI first listed
2006-03-16
NPI last updated
2024-05-09
NPI record certified
2024-05-09

This is when the NPI record was last certified, not a medical board exam.